Secondary Logo

Journal Logo

Abstracts: ASAIO Bioengineering/tissue Engineering Abstracts

MARS TREATMENT FOR ALF IN HEPATITIS B PATIENTS UNDERGOING CHEMOTHERAPY IN PATIENTS WITH NON HODGKIN’S LYMPHOMA

Novelli, Gilnardo1; Rossi, Massimo1; Ferretti, Giancarlo1; Ferretti, Stefano1; Mennini, Gianluca1; Novelli, Luigi1; Antonellis, Fabio1; Nudo, Francesco1; Berloco, Pasquale B1

Author Information
  • Free

Hepatitis B virus is a serious cause of morbidity and mortality in hepatitis B surface antigen-positive patients treated with chemotherapy. Because the hepatitis is related to HBV virological reactivation, application of effective antiviral therapy to HBV, such as Lamivudine, has been attempted. Despite the use of these antiviral agents at the time of clinical hepatitis, some HBsAg-positive patients still developed hepatic failure and died. In our experience we used the Molecular Adsorbent Recirculating System (MARS), to treat five HBsAG positive lymphoma patients with ALF due to chemotherapy despite lamivudine treatment. The parametrers that we monitored, before and after each treatment, were neurological status (EEG,cerebral CT,GCS), haemodinamic parameters, acid base equilibrium and blood gas analysis. We also monitored hepatic and renal function Inclusion Criteria were the same of King’s College Hospital. Statistical analysis (t student methods) showed significant results (p < 0,01). Tree of five patients are alive without signs of reactivation of viral and haematological diseases (follow-up one year).The two patients dead started MARS treatment too late: Glascow coma score IV grade, haemodinamic instability, mechanic ventilator assistance. In spite of the limited number of cases of our study we believe that MARS can be applied in this patients with high tollerance and good results, but the treatment has to start at the first signs of hepatic failure.

Copyright © 2005 by the American Society for Artificial Internal Organs